[Meta-analysis and trial sequential analysis of Tanreqing Injection in treatment of severe pneumonia in elderly].

• DOI: 10.19540/j.cnki.cjcmm.20231025.501
• Publication Date: 2024-02-01
• Authors: Yanhui Jiang; Shi-Hao Ni; Xian-Jin Zhang; Jie Huang; Hao-Hui Liu; Lu Xu; Huili Liao; Dongsheng Xue; Zhong-Qi Yang
• Keywords: Procalcitonin; White blood cell

This study aimed to systematically evaluate the effectiveness and safety of Tanreqing Injection in treatment severe pneumonia elderly. Eighteen randomized controlled trials(RCTs) involving 1 457 elderly patients with were included after conducting searches both Chinese English databases as well clinical trial registration platforms. The quality studies was assessed using Cochrane risk bias assessment tool. Meta-analysis conducted RevMan 5.4 Stata 17 software, sequential analysis(TSA) performed TSA 0.9.5.10 beta software. results showed that compared conventional western medicine treatment, + medical significantly improved pneumonia(RR=1.26, 95%CI[1.20, 1.32], P<0.000 01), arterial oxygen partial pressure(SMD=6.23, 95%CI[3.29, 9.18], 1), oxygenation index(SMD=11.72, 95%CI[4.41, 19.04], P=0.002), reduce procalcitonin(SMD=-6.16, 95%CI[-8.10,-4.21], C-reactive protein(SMD=-8.50, 95%CI[-11.05,-5.96], white blood cell count(SMD=-4.56, 95%CI[-5.73,-3.39], shortened duration fever(SMD=-3.12, 95%CI[-4.61,-1.63], cough(SMD=-4.84, 95%CI[-6.90,-2.79], lung rales(SMD=-0.99, 95%CI[-1.54,-0.44], P=0.000 4), mechanical ventilation time(SMD=-3.26, 95%CI[-5.03,-1.50], 3), increase CD4~+ T-cell levels(SMD=6.73, 95%CI[5.23, 8.23], 01) CD8~+ levels(SMD=7.47, 95% CI[5.32, 9.61], no significant adverse reactions. confirmed stability reliability related effectiveness. suggests Injection, a medicinal preparation, has therapeutic effect good profile patients. Due limited studies, high-quality RCT is still needed provide evidence support for above conclusions.